Reference
1. Nezos A, Papageorgiou A, Fragoulis G, Ioakeimidis D, Koutsilieris M,
Tzioufas AG, et al. B-cell activating factor genetic variants in
lymphomagenesis associated with primary Sjogren’s syndrome. J Autoimmun.
2014 Jun;51:89–98.
2. Kintrilis N, Gravani F, Rapti A, Papaioannou M, Flessa CM, Nezos A,
et al. Subclinical atherosclerosis profiles in rheumatoid arthritis and
primary Sjögren’s syndrome: The impact of BAFF genetic variations.
Rheumatology (Oxford). 2022 Jun 11;keac337.
3. Santillan-Lopez E, Francisco Munoz-Valle J, Oregon-Romero E,
Espinoza-Garcia N, Alejandra Trevino-Talavera B, Celeste
Salazar-Camarena D, et al. Analysis of TNFSF13B polymorphisms and BAFF
expression in rheumatoid arthritis and primary Sjogren’s syndrome
patients. Mol Genet Genom Med. 2022 Jun;10(6):e1950.
4. Zeng Q, Wen J, Zheng L, Zeng W, Chen S, Zhao C. Identification of
immune-related diagnostic markers in primary Sjogren’s syndrome based on
bioinformatics analysis. ANN TRANSL MED. 2022 Apr;10(8):487.
5. Loureiro-Amigo J, Franco-Jarava C, Perurena-Prieto J, Palacio C,
Martínez-Valle F, Soláns-Laqué R. Serum CXCL13, BAFF, IL-21 and IL-22
levels are related to disease activity and lymphocyte profile in primary
Sjögren’s syndrome. Clin Exp Rheumatol. 2021;39 Suppl 133(6):131–9.
6. Carrillo-Ballesteros FJ, Palafox-Sanchez CA, Franco-Topete RA,
Munoz-Valle JF, Orozco-Barocio G, Martinez-Bonilla GE, et al. Expression
of BAFF and BAFF receptors in primary Sjogren’s syndrome patients with
ectopic germinal center-like structures. Clin Exper Med. 2020
Nov;20(4):615–26.
7. James JA, Guthridge JM, Chen H, Lu R, Bourn RL, Bean K, et al. Unique
Sjögren’s syndrome patient subsets defined by molecular features.
Rheumatology (Oxford). 2020 Apr 1;59(4):860–8.
8. Marín-Rosales M, Cruz A, Salazar-Camarena DC, Santillán-López E,
Espinoza-García N, Muñoz-Valle JF, et al. High BAFF expression
associated with active disease in systemic lupus erythematosus and
relationship with rs9514828C>T polymorphism in TNFSF13B
gene. Clin Exp Med. 2019 May 1;19(2):183–90.
9. Baldini C, Ferro F, Elefante E, Bombardieri S. Biomarkers for
Sjögren’s syndrome. Biomark Med. 2018 Mar;12(3):275–86.
10. Teos LY, Alevizos I. Genetics of Sjogren’s syndrome. Clin Immunol.
2017 Sep;182:41–7.
11. Mavragani CP. Mechanisms and New Strategies for Primary Sjögren’s
Syndrome. Annu Rev Med. 2017 Jan 14;68:331–43.
12. Steri M, Orru V, Idda ML, Pitzalis M, Pala M, Zara I, et al.
Overexpression of the Cytokine BAFF and Autoimmunity Risk. N Engl J Med.
2017 Apr 27;376(17):1615–26.
13. Thompson N, Isenberg DA, Jury EC, Ciurtin C. Exploring BAFF: its
expression, receptors and contribution to the immunopathogenesis of
Sjögren’s syndrome. Rheumatology (Oxford). 2016 Sep;55(9):1548–55.
14. Deng F, Chen J, Zheng J, Chen Y, Huang R, Yin J, et al. Association
of BAFF and IL-17A with subphenotypes of primary Sjogren’s syndrome. Int
J Rheum Dis. 2016 Jul;19(7):715–20.
15. Lee SJ, Oh HJ, Choi BY, Jang YJ, Lee JY, Park JK, et al. Serum
25-Hydroxyvitamin D3 and BAFF Levels Are Associated with Disease
Activity in Primary Sjogren’s Syndrome. J Immunol Res.
2016;2016:5781070.
16. Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The
BAFF/APRIL system: Emerging functions beyond B cell biology and
autoimmunity. Cytokine & Growth Factor Reviews. 2013 Jun
1;24(3):203–15.
17. Brkic Z, Maria NI, van Helden-Meeuwsen CG, van de Merwe JP, van
Daele PL, Dalm VA, et al. Prevalence of interferon type I signature in
CD14 monocytes of patients with Sjogren’s syndrome and association with
disease activity and BAFF gene expression. Ann Rheum Dis. 2013
May;72(5):728–35.
18. Pers JO, Lahiri A, Tobon GJ, Youinou P. Pathophysiological cytokine
network in primary Sjogren’s syndrome. Presse Med. 2012 Sep;41(9 Pt
2):e467-74.
19. Lahiri A, Pochard P, Le Pottier L, Tobon GJ, Bendaoud B, Youinou P,
et al. The complexity of the BAFF TNF-family members: Implications for
autoimmunity. J Autoimmun. 2012 Sep;39(3):189–98.
20. Vosters JL, Roescher N, Polling EJ, Illei GG, Tak PP. The expression
of APRIL in Sjo¨ gren’s syndrome: aberrant expression of APRIL in the
salivary gland. RHEUMATOLOGY. 2012 Sep;51(9):1557–62.
21. Mariette X, Gottenberg JE. Pathogenesis of Sjogren’s syndrome and
therapeutic consequences. Curr Opin Rheumatol. 2010 Sep;22(5):471–7.
22. Ota M, Duong BH, Torkamani A, Doyle CM, Gavin AL, Ota T, et al.
Regulation of the B Cell Receptor Repertoire and Self-Reactivity by
BAFF. J Immunol. 2010 Oct 1;185(7):4128–36.
23. Vadacca M, Margiotta D, Sambataro D, Buzzulini F, Lo Vullo M, Rigon
A, et al. [BAFF/APRIL pathway in Sjögren syndrome and systemic lupus
erythematosus: relationship with chronic inflammation and disease
activity]. Reumatismo. 2010;62(4):259–65.
24. Nikolov NP, Illei GG. Pathogenesis of Sjogren’s syndrome. Curr Opin
Rheumatol. 2009 Sep;21(5):465–70.
25. Nossent JC, Lester S, Zahra D, Mackay CR, Rischmueller M.
Polymorphism in the 5 ’ regulatory region of the B-lymphocyte activating
factor gene is associated with the Ro/La autoantibody response and serum
BAFF levels in primary Sjogren’s syndrome. RHEUMATOLOGY. 2008
Sep;47(9):1311–6.
26. Daridon C, Devauchelle V, Hutin P, Le Berre R, Martins-Carvalho C,
Bendaoud B, et al. Aberrant expression of BAFF by B lymphocytes
infiltrating the salivary glands of patients with primary Sjögren’s
syndrome. Arthritis Rheum. 2007 Apr;56(4):1134–44.
27. Ittah M, Miceli-Richard C, Gottenberg JE, Lavie F, Lazure T, Ba N,
et al. B cell-activating factor of the tumor necrosis factor family
(BAFF) is expressed under stimulation by interferon in salivary gland
epithelial cells in primary Sjogren’s syndrome. Arthritis Res Ther.
2006;8(2):R51.
28. Szodoray P, Alex P, Jonsson MV, Knowlton N, Dozmorov I, Nakken B, et
al. Distinct profiles of Sjögren’s syndrome patients with ectopic
salivary gland germinal centers revealed by serum cytokines and BAFF.
Clin Immunol. 2005 Nov;117(2):168–76.
29. Szodoray P, Jonsson R. The BAFF/APRIL system in systemic autoimmune
diseases with a special emphasis on Sjogren’s syndrome. Scand J Immunol.
2005 Nov;62(5):421–8.
30. Matsushita T, Sato S. [The role of BAFF in autoimmune diseases].
Nihon Rinsho Meneki Gakkai Kaishi. 2005 Oct;28(5):333–42.
31. Gottenberg JE, Busson M, Cohen-Solal J, Lavie F, Abbed K, Kimberly
RP, et al. Correlation of serum B lymphocyte stimulator and beta2
microglobulin with autoantibody secretion and systemic involvement in
primary Sjogren’s syndrome. Ann Rheum Dis. 2005 Jul;64(7):1050–5.
32. Mackay F, Sierro F, Grey ST, Gordon TP. The BAFF/APRIL system: an
important player in systemic rheumatic diseases. Curr Dir Autoimmun.
2005;8:243–65.
33. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K.
Association between circulating levels of the novel TNF family members
APRIL and BAFF and lymphoid organization in primary Sjogren’s syndrome.
J Clin Immunol. 2005 May;25(3):189–201.
34. Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette
X. Expression of BAFF (BLyS) in T cells infiltrating labial salivary
glands from patients with Sjögren’s syndrome. J Pathol. 2004
Apr;202(4):496–502.
35. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The
level of BLyS (BAFF) correlates with the titre of autoantibodies in
human Sjogren’s syndrome. Ann Rheum Dis. 2003 Feb;62(2):168–71.
36. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, et
al. Association of BAFF/BLyS overexpression and altered B cell
differentiation with Sjögren’s syndrome. J Clin Invest. 2002
Jan;109(1):59–68.
37. Gottenberg JE, Sellam J, Ittah M, Lavie F, Proust A, Zouali H, et
al. No evidence for an association between the-871 T/C promoter
polymorphism in the B-cell-activating factor gene and primary Sjogren’s
syndrome. Arthritis Res Ther. 2006;8(1):R30.
38. Flessa CM, Zampeli E, Evangelopoulos ME, Natsis V, Bodewes ILA,
Huijser E, et al. Genetic Variants of the BAFF Gene and Risk of Fatigue
Among Patients With Primary Sjogren’s Syndrome. Front Immunol. 2022 Mar
15;13:836824.